Pritelivir, an investigational antiviral for herpes simplex virus, demonstrated strong efficacy in a phase 3 trial, with 62.7% of immunocompromised patients achieving lesion healing. The ...
Pritelivir, an investigational antiviral drug for herpes simplex virus, demonstrated “superior efficacy” in healing lesions ...
Regeneron-Sanofi’s Dupixent recommended by CHMP for EU approval to treat CSU in young children with ongoing symptoms despite treatment: Tarrytown, New York Wednesday, March 4, 2 ...
Chinese assets have outgrown a “bargain basement” label as the upfront value of licensing deals involving them has increased, ...
Neuspera® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, announced positive 12-month outcomes1 from its pivotal trial of the Neuspera SNM ...
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chr ...
LCGC International's "LC Troubleshooting" column editor Dwight Stoll and colleagues pay tribute to the late Peter Carr, an ...
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to ...
Franzen wants to move DuPont from the materials sector, where it is considered a specialty chemicals company, to somewhere in ...
Dupilumab development program Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical ...
In the U.S., a supplemental Biologics License Application (sBLA) has been accepted for review seeking approval for Dupixent in certain children aged 2 to 11 years with CSU. The U.S. Food and Drug ...
Dr. Todd Maderis, ND Exploring immune dysregulation, viral reactivation, mitochondrial impairment, and treatment implications in post-EBV fatigue syndromes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results